. Author manuscript; available in PMC: 2011 May 13.

Published in final edited form as: J Cell Biochem. 2010 May;110(1):171–181. doi: 10.1002/jcb.22523

TABLE I.

Anti-Tumor Activity of B-DIM, Erlotinib, Gemcitabine, and Their Combination in COLO-357-Bearing CB17 SCID Mice

Agent	No. of animals (bilateral)	Route	T/C (%)	T–C (days)	Log₁₀ kill		Activity score
Agent	No. of animals (bilateral)	Route	T/C (%)	T–C (days)	Gross	Net	Activity score
Control	7	N/A	100	0	0.0	0.0	N/A
B-DIM	7	PO	88	2	0.37	N/A	−
Erlotinib	7	IP	89	3	0.55	N/A	−
Gemcitabine	7	IV	79	4	0.74	N/A	+
B-DIM + erlotinib	7	PO + IP	74	7	1.3	N/A	++
B-DIM + gemcitabine	7	PO + IV	76	9	1.7	N/A	++
Erlotinib + gemcitabine	7	IP + IV	59	14	2.6	0.37	+++
B-DIM + erl + gem	7	PO + IP + IV	47	22	4.1	1.86	++++

Doubling time was estimated at 1.62 days.

The drugs were administered for 12 consecutive days.